logo

IMUX

Immunic·NASDAQ
--
--(--)
--
--(--)
2.86 / 10
Underperform

Corporate fundamentals rate concerning at 2.9/10. Beneficial factors: Profit-MV and Cash-MV, however risks emerge in Net profit / Total profit (%) and Asset-MV. Resultant assessment: prudent.

Fundamental(2.86)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight13.04%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight11.46%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-1.01%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight19.52%
1M Return7.79%
PB-ROE
Value0.98
Score2/3
Weight27.40%
1M Return10.68%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.28%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.66%
1M Return0.86%
Asset-MV
Value-0.50
Score0/3
Weight6.67%
1M Return2.94%
Cash-MV
Value-0.07
Score2/3
Weight19.55%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.58%
1M Return-0.30%
Is IMUX fundamentally strong?
  • IMUX scores 2.86/10 on fundamentals and holds a Premium valuation at present. Backed by its -538.38% ROE, 0.00% net margin, -0.73 P/E ratio, 7.10 P/B ratio, and 34.96% earnings growth, these metrics solidify its Underperform investment rating.